Literature DB >> 9652756

Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10.

R Dummer1, F Y Yue, J Pavlovic, R Geertsen, C Döhring, K Moelling, G Burg.   

Abstract

The immunostimulatory capacities of B7.1-and B7.2- expressing melanoma cells were investigated. A365, 960306 and 950504 melanomas, established from nodular melanoma lesions, were retrovirally transduced. Irradiated B7-, B7.1+ and B7.2+ melanoma cells were co-cultured with autologous or allogeneic peripheral blood mononuclear cells (PBMCs). Proliferation was assessed by [3H]thymidine uptake. mRNA encoding for interleukin 2 (IL-2), IL-4, IL-10 and interferon gamma (IFN-gamma) was determined. IFN-gamma, IL-2, IL-4 and IL-10 secretion were quantitated by ELISA. B7.1+ and B7.2+ melanomas induced proliferation of PBMCs and mRNA for IL-2 and IFN-gamma. After co-incubation of transduced melanoma cells with PBMCs, high levels of IL-10 were detectable in the supernatant. The presence of neutralizing anti-IL-10 antibodies resulted in enhanced proliferation and IL-2 and IFN-gamma secretion. Our data indicate that B7.1- and B7.2-transduced melanoma cells trigger lymphocytic proliferation with transcription of IL-10, IL-2 and IFN-gamma. Blocking of IL-10 augments these effects. Gene therapy protocols using tumour cells as a vaccine have to consider the adverse effects of IL-10.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652756      PMCID: PMC2150196          DOI: 10.1038/bjc.1998.234

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain).

Authors:  R Dummer; P W Heald; F O Nestle; E Ludwig; E Laine; S Hemmi; G Burg
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

2.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy.

Authors:  V K Kuchroo; M P Das; J A Brown; A M Ranger; S S Zamvil; R A Sobel; H L Weiner; N Nabavi; L H Glimcher
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

3.  In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity.

Authors:  R W Denfeld; A Dietrich; C Wuttig; E Tanczos; J M Weiss; W Vanscheidt; E Schöpf; J C Simon
Journal:  Int J Cancer       Date:  1995-07-28       Impact factor: 7.396

4.  Production of cytokines by human melanoma cells and melanocytes.

Authors:  S Krüger-Krasagakes; K Krasagakis; C Garbe; T Diamantstein
Journal:  Recent Results Cancer Res       Date:  1995

5.  Maintenance of clonal anergy by endogenously produced IL-10.

Authors:  J C Becker; C Czerny; E B Bröcker
Journal:  Int Immunol       Date:  1994-10       Impact factor: 4.823

6.  A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes.

Authors:  J Sulé-Suso; F Arienti; C Melani; M P Colombo; G Parmiani
Journal:  Eur J Immunol       Date:  1995-10       Impact factor: 5.532

7.  The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. Correlation with binding to LFA-1.

Authors:  P L Reilly; J R Woska; D D Jeanfavre; E McNally; R Rothlein; B J Bormann
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

8.  Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.

Authors:  T F Gajewski; F Fallarino; C Uyttenhove; T Boon
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

9.  B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

Authors:  G J Freeman; V A Boussiotis; A Anumanthan; G M Bernstein; X Y Ke; P D Rennert; G S Gray; J G Gribben; L M Nadler
Journal:  Immunity       Date:  1995-05       Impact factor: 31.745

Review 10.  [How do melanoma cells circumvent the immune response? Consequences for future therapy attempts and current biopsy processing].

Authors:  R Dummer; R Böni
Journal:  Schweiz Med Wochenschr       Date:  1995-09-02
View more
  3 in total

1.  Inflammatory gradient in Barrett's oesophagus: implications for disease complications.

Authors:  R C Fitzgerald; S Abdalla; B A Onwuegbusi; P Sirieix; I T Saeed; W R Burnham; M J G Farthing
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 2.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

3.  Low IL-23 levels in peripheral blood and bone marrow at diagnosis of acute leukemia in children increased with the elimination of leukemic burden.

Authors:  Archontis Zampogiannis; Christina Piperi; Margarita Baka; Iliana Zoi; Athanasios G Papavassiliou; Maria Moschovi
Journal:  J Cell Mol Med       Date:  2021-07-08       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.